EC Number   |
Recommended Name  |
Application |
|---|
    4.3.2.1 | argininosuccinate lyase |
diagnostics |
the enzyme may be used as a candidate marker for serodiagnosis of brucellosis |
| 4.3.2.1 | argininosuccinate lyase |
diagnostics |
the urea cycle metabolite argininosuccinate is a common metabolic biomarker of FH deficiency |
| 3.5.1.13 | aryl-acylamidase |
diagnostics |
relative ratios of aryl acylamidase activity to butyrylcholinesterase activity on butyrylchlolinesterase protein could serve as a diagnostic marker in comparison to aspartate aminotransferases and gamma-glutamyltransferase activities, in patients with liver disorders |
| 3.1.8.1 | aryldialkylphosphatase |
diagnostics |
decrease of serum PON1 activities is usually related to many chronic diseases, such as atherosclerosis, diabetes, cancers, migraine, pulmonary tuberculosis, polycystic ovary syndrome, gastroesophageal malignancies, depression, nephritic syndrome, hemodialysis, metabolic syndrome, and liver disease. Determination of PON1 activity has a significant diagnostic value in predicting disease status. PON1 shows very good adaptability in assay development with different substrates, PON1 substrate exhibit many degrees of freedom in docking simulations |
| 3.5.1.1 | asparaginase |
diagnostics |
the enzyme is a marker of chemotherapy dose modification during the induction phase in children with acute lymphoblastic leukemia, overview |
| 1.14.14.3 | bacterial luciferase |
diagnostics |
expression of the bacterial luciferase system in mammalian cells for generation of bioreporters for in vivo monitoring and diagnostics technology, method evaluation and optimization, overview |
| 2.4.1.102 | beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase |
diagnostics |
C2GnT1 might become a prognostic factor for endometrial carcinoma. Patients with C2GnT1 overexpression show significantly shorter survival, multivariable analysis also indicate that 2GnT1 overexpression is an independent prognostic factor |
| 2.4.1.102 | beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase |
diagnostics |
detection of core2 beta-1,6-N-acetylglucosaminyltransferase in post-digital rectal examination urine is a reliable indicator for extracapsular extension of prostate cancer. The number of GCNT1-positive cases is significantly lower in cases of organ-confined disease than in cases of extracapsular extension. GCNT1-negative tumors are a associated with significantly better prostate-specific antigen (PSA)-free survival compared with GCNT1-positive tumors. Multivariate analysis reveals that detection of GCNT1 expression is an independent risk factor for prostate-specific antigen recurrence |
| 2.4.1.102 | beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase |
diagnostics |
GCNT1 expression in prostate biopsy specimen is a significant and independent predictor of recurrence after radical prostatectomy, which can be used in pre-treatment decision making for the patient |
| 2.4.1.102 | beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase |
diagnostics |
possible role of GCNT3 gene expression as prognostic marker in colon cancer. Low CNT3 expression is a promising prognostic biomarker for colon cancer that could be used to identify early-stage colon cancer patients at high risk of relapse. The enzyme might also constitute a biomarker to monitor tumour response to chemotherapy in cancer patients |
| 2.4.1.102 | beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase |
diagnostics |
GCNT3 might be an essential glycosylation-related molecule in colorectal cancer and epithelial ovarian cancer progression, with potential interest as a predictive biomarker of response to chemotherapy. GCNT3 high-expressing Stage III-IV EOC patients have better response to conventional treatment and clinical outcome. Clinical relevance of GCNT3 expression in epithelial ovarian cancer (EOC), role of GCNT3 as a biomarker for cancer patients, overview |
| 2.4.1.144 | beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase |
diagnostics |
GnT-III expression levels are elevated in high-grade serous ovarian carcinoma tissues and correlate with reduced survival |
| 2.7.11.15 | beta-adrenergic-receptor kinase |
diagnostics |
GRK2 levels in heart and peripheral lymphocytes correlate well, therefore the lymphocytic enzyme level might be a very suitable marker for determination for the sympathetic drive to heart failure during clinical course and treatment of human congestive heart failure patients |
| 1.13.11.63 | beta-carotene 15,15'-dioxygenase |
diagnostics |
genotyping AI rams for c.196C-T can be used in selection against the yellow fat trait |
| 3.2.1.23 | beta-galactosidase |
diagnostics |
the enzyme is a reliable marker for the course of replicative cell senescence |
| 3.2.1.31 | beta-glucuronidase |
diagnostics |
the enzyme is useful in analysis of phytoestrogens and related compounds in human biofluids, e.g. urine |
| 3.2.1.31 | beta-glucuronidase |
diagnostics |
beta-glucuronidase activity is a sensitive biomarker to assess low-level organophosphorus insecticide exposure, e.g. plasma BG activity for low-level organophosphorus-exposure compared to BChE activity, overview |
| 3.2.1.31 | beta-glucuronidase |
diagnostics |
a technique for MPS VII diagnosis is adapted for smaller amounts of sample and reagents. That will facilitate the use of smaller amounts of samples, which may be used for other techniques and to save material. Given the importance of early MPS VII diagnosis due to the severity of the disease, using reliable diagnostic techniques in dried blood spots is essential |
| 3.5.2.6 | beta-lactamase |
diagnostics |
diagnostic utility of the combination of Syn 2190 and cefotetan in a disk test for the detection of clinical isolates of Klebsiella sp. producing plasmid-mediated AmpC beta-lactamases. The sensitivity of this test is 91%, the specificity is 100%, and the reproducibility is 100% |
| 3.2.1.52 | beta-N-acetylhexosaminidase |
diagnostics |
a spectrophotometric method for the determination of lysosomally derived N-acetyl-beta-D-hexosaminidase in synovial fluid on a microplate reader is optimized to improve its utility. The assay is sufficiently sensitive for small volumes of synovial fluid, and is useful for the clinical diagnosis of joint diseases |
| 1.3.3.5 | bilirubin oxidase |
diagnostics |
BOD is used for diagnostic analysis of bilirubin in serum |
| 1.3.3.5 | bilirubin oxidase |
diagnostics |
the BOD activity catalyzing the oxidation of bilirubin to biliverdin can be used for the diagnosis of jaundice and hyperbilirubinemia |
| 1.3.1.24 | biliverdin reductase |
diagnostics |
antiapoptotic effect of the enzyme in cancers portens strategies for developing novel biomarkers and effective treatment ways for cancer patients |
| 1.3.1.24 | biliverdin reductase |
diagnostics |
peripheral biomarker for the early diagnosis of Alzheimer's disease |
| 6.3.4.15 | biotin-[biotin carboxyl-carrier protein] ligase |
diagnostics |
BirA can be useful for specific in vivo labeling of proteins in cell cultures by biotinylation |
| 6.3.4.10 | biotin-[propionyl-CoA-carboxylase (ATP-hydrolysing)] ligase |
diagnostics |
the HCS assay using rat liver apopropionyl-CoA carboxylase as substrate is useful for enzymatic diagnosis of HCS deficiency |
| 3.5.1.12 | biotinidase |
diagnostics |
BTD is a biomarker for the hepatic glycogen storage disease, overview |
| 3.5.1.12 | biotinidase |
diagnostics |
BTD is a potential serological biomarker for the detection of breast cancer to use with plasma |
| 3.5.1.12 | biotinidase |
diagnostics |
loss of overall biotinidase expression is a marker for papillary thyroid cancer aggressiveness acting as a predictor of disease progression and prognosis |
| 3.4.22.B29 | calpain 9 |
diagnostics |
low calpain-9 is associated with adverse disease-specific survival following endocrine therapy in breast cancer, but no associations are observed between calpain-9 expression and clinicopathological variables |
| 4.2.1.1 | carbonic anhydrase |
diagnostics |
activity of carbonic anhydrase is significantly lower in patients with renal cell carcinoma than in controls. The marker carbonic anhydrase might be potentially important as an additional biochemical tool for diagnosing renal cell carcinoma |
| 1.1.1.184 | carbonyl reductase (NADPH) |
diagnostics |
expression of CBR mRNA is a significant prognostic factor in nonsmall-cell lung cancer and is inversely associated with tumor progression and angiogenesis |
| 3.1.1.1 | carboxylesterase |
diagnostics |
use of enzyme as a more sensitive biomarker for exposure to organophosphate than acetylcholinesterase. Enzyme is not suitable as a biomarker for pyrethroid exposure |
| 3.1.1.1 | carboxylesterase |
diagnostics |
possible use of the enzyme as a protein biomarker and drug target for lung cancer |
| 3.1.1.1 | carboxylesterase |
diagnostics |
development of bacterial carboxylesterase biological recognition elements for cocaine detection |
| 3.4.17.2 | carboxypeptidase B |
diagnostics |
the enzyme is a serum marker for acute pancreatitis and pancreatic graft injection |
| 3.4.17.10 | carboxypeptidase E |
diagnostics |
CPE serves as a marker for pulmonary endocrine tumor cells in the lung, enzyme expression correlates with a good prognosis, while expression of gamma-glutamyl hydrolase is correlated with a poor prognosis, overview |
| 3.4.17.10 | carboxypeptidase E |
diagnostics |
carboxypeptidase E is a prediction marker for tumor recurrence in early-stage hepatocellular carcinoma |
| 3.4.17.10 | carboxypeptidase E |
diagnostics |
N-terminal truncated carboxypeptidase E (CPEDELTAN) expression is associated with poor prognosis of lung adenocarcinoma. CPEDELTAN may present a molecular biomarker for predicting recurrence and metastasis of lung adenocarcinoma |
| 3.4.17.12 | carboxypeptidase M |
diagnostics |
CPM, a gene that encodes carboxypeptidase M, is consistently amplified in liposarcomas but not in different subtypes of lipoma or normal fat, CPM could be used as an alternative and novel diagnostic tool for these tumors |
| 3.4.17.12 | carboxypeptidase M |
diagnostics |
expression is positively correlated with overall survival and negatively correlated with recurrence, lymph node invasion, and N stage in colorectal cancer |
| 3.4.17.20 | Carboxypeptidase U |
diagnostics |
the activation peptide of procarboxypeptidase B, set free during activation of procarboxypeptidase B, is a marker for acute pancreatitis |
| 1.1.1.108 | carnitine 3-dehydrogenase |
diagnostics |
the L-carnitine oxidation step can be exploited for spectroscopic L-carnitine determination in biological fluids |
| 3.4.22.55 | caspase-2 |
diagnostics |
high level of inactive, non-processed caspase-2 together with caspase-3 is used as a predictor of survival and complete remission in adults with acute myeloblastic or lymphoblastic leukemias |
| 3.4.22.56 | caspase-3 |
diagnostics |
a simple biochemical assay of caspase-3 activity in blood, may be useful for predicting the disposition of drugs that undergo extensive conjugation and biliary elimination like silymarin in patients with liver disease, caspase-3 activity correlates with the amount of silymarin conjugates, e.g. silychristin and silybin A and B, and is 5fold higher in the HCV cirrhosis cohort, overview |
| 3.4.22.56 | caspase-3 |
diagnostics |
active caspase-3 immunostaining is considered as a highly reliable and specific morphological marker of early apoptosis |
| 3.4.22.56 | caspase-3 |
diagnostics |
caspase-3 activity is a marker for apoptosis in gut epithelium, leading to impairment of the gastrointestinal mucosal barrier, that contributes to progression of HIV infection, immunohistochemical staining of cleaved caspase-3, overview |
| 3.4.22.56 | caspase-3 |
diagnostics |
caspase-3 activity is a marker for cell death, e.g. in microglia, overview |
| 3.4.22.56 | caspase-3 |
diagnostics |
caspase-3 can act as apoptosis marker |
| 3.4.22.56 | caspase-3 |
diagnostics |
caspase-3 is a helpful indicator of apoptosis induction, e.g. in mammary carcinomas |
| 3.4.22.56 | caspase-3 |
diagnostics |
caspase-3 is a marker for apoptosis, e.g. useful in patients with urothelial carcinoma of the upper urinary tract, overview |
| 3.4.22.56 | caspase-3 |
diagnostics |
caspase-3 is a marker of apoptotic cell death in embryonic fibroblasts, NIH-3T3 and WST-1 cells |
| 3.4.22.59 | caspase-6 |
diagnostics |
excessive activation of caspase-6 is an early marker of neuronal dysfunction and implicated in the pathogenesis of Huntington disease, Alzheimer's disease and other forms of cognitive impairment |
| 1.11.1.6 | catalase |
diagnostics |
catalase activity is significantly higher in patients with renal cell carcinoma than in controls. The marker catalase might be potentially important as an additional biochemical tool for diagnosing renal cell carcinoma |
| 3.4.22.1 | cathepsin B |
diagnostics |
CATB is a potent and independent prognostic marker for resectable pancreatic adenocarcinoma |
| 3.4.22.1 | cathepsin B |
diagnostics |
cathepsin B is a biologic marker reflecting the clinical state of inflammatory disease |
| 3.4.22.1 | cathepsin B |
diagnostics |
increased cathepsin-B expression is predictive of more aggressive tumour behaviour over time and can be regarded as an unfavourable and independent tumour marker for endometrial cancer patients with a long follow-up |
| 3.4.22.1 | cathepsin B |
diagnostics |
the enzyme might be a useful marker for cancer development |
| 3.4.22.1 | cathepsin B |
diagnostics |
cathepsin B activity can be a useful marker of oocyte quality |
| 3.4.22.1 | cathepsin B |
diagnostics |
cathepsin B is a possible prognostic biomarker for the aggressiveness of ovarian cancer, overview |
| 3.4.22.1 | cathepsin B |
diagnostics |
cathepsin B is an important biomarker for the stratification of glioblastoma patients with respect to survival |
| 3.4.22.41 | cathepsin F |
diagnostics |
paragonimiasis, caused by the lung fluke Paragonimus, is a major food-borne helminthic disease. Differential diagnosis of paragonimiasis from tuberculosis and other infectious granulomas in the lung is a prerequisite to proper management of patients. Diverse Cysteine proteases of Paragonimus westermani of the cathepsin F family participate in inducing specific antibody responses. Most Paragonimus westermani cathepsin F, except for PwCP2 (AAF21461),which shows negligible antibody responses, might be applicable for paragonimiasis serodiagnosis |
| 3.4.22.41 | cathepsin F |
diagnostics |
paragonimiasis, caused by the lung fluke Paragonimus, is a major food-borne helminthic disease. Differential diagnosis of paragonimiasis from tuberculosis and other infectious granulomas in the lung is a prerequisite to proper management of patients. Diverse Cysteine proteases of Paragonimus westermani of the cathepsin F family participate in inducing specific antibody responses. Most Paragonimus westermani cathepsin F, except for PwCP2 (Q9U0G8),which shows negligible antibody responses, might be applicable for paragonimiasis serodiagnosis |
| 3.4.22.38 | cathepsin K |
diagnostics |
to assess better the biology of CatK activity in vivo, a novel near-infrared fluorescence (NIRF) probe for imaging of CatK is developed |
| 3.4.22.15 | cathepsin L |
diagnostics |
specificity and sensitivity of cathepsin L activity is a diagnostic biomarker for proteinuria |
| 3.4.22.15 | cathepsin L |
diagnostics |
the enzyme is a candidate antigen to diagnose porcine cysticercosis via ELISA immunoassay |
| 3.4.22.B49 | cathepsin L1 |
diagnostics |
a monoclonal antibody (MoAb) against recombinant Fasciola gigantica cathepsin L1H (rFgCatL1H) is produced by hybridoma technique using spleen cells from BALB/c mice immunized with recombinant proFgCatL1H (rproFgCatL1H). This MoAb is an immunoglobulin (Ig)G1 with kappa light chain isotype. The MoAb reacts specifically with rproFgCatL1H, the native FgCatL1H at a molecular weight (MW) 38-48 kDa in the extract of whole body (WB) of metacercariae and newly excysted juvenile (NEJ) and cross-reacted with rFgCatL1 and native FgCatLs at MW 25 to 28 kDa in WB of 2- and 4-week-old juveniles, adult, and adult excretory-secretory (ES) fractions by immunoblotting and indirect ELISA. It does not cross-react with antigens in WB fractions from other parasites. FgCatL1H and its MoAb may be used for immunodiagnosis of both early and late fasciolosis in ruminants and humans |
| 3.4.22.B49 | cathepsin L1 |
diagnostics |
analysis of the diagnostic values of the three different clades of cathepsin Ls, FhCL1, FhCL2, and FhCL5, from adult flukes in an ELISA, test of sera from sheep and cattle naturally infected with Fasciola hepatica, of cross-reactive antibodies, overview. For sheep sera, the sensitivity is 100% for the three rFhpCLs, while for cattle sera, the highest sensitivity is obtained using rFhpCL2 (97%), being equal for both rFhpCL1 and rFhpCL5 (87.9%), after adjusting cut-offs for maximum specificity |
| 3.4.22.B49 | cathepsin L1 |
diagnostics |
design and synthesis of a new peptide derived from Fasciola gigantica cathepsin L1 with potential application in serodiagnosis of fascioliasis via ELISA, overview. Cathepsin L1 as antigen for serodiagnosis of animal fasciolosis |
| 3.4.22.B49 | cathepsin L1 |
diagnostics |
recombinant proFgCatL1H protein expressed from Pichia pastoris is mixed with Freund's adjuvants and used to subcutaneously immunize mice, the mice are then challenged with metacercariae of Fasciola gigantica. The percentage of worm protection in the rproFgCatL1H-vaccinated mice compared to the non-immunized and adjuvant control mice are approximately 62.7% and 66.1%, respectively. Anti-rproFgCatL1H antisera collected from vaccinated mice react specifically with rproFgCatL1H and other cathepsin L isoforms of Fasciola gigantica, but the antibodies do not crossreact with antigens from other trematode and nematode parasites, including Eurytrema pancreaticum, Opisthorchis viverrini, Fischoederius cobboldi, Cotylophoron cotylophorum, Gigantocotyle explanatum, Paramphistomum cervi, and Setarialabiato papillosa |
| 3.4.22.B60 | cathepsin L2 |
diagnostics |
analysis of the diagnostic values of the three different clades of cathepsin Ls, FhCL1, FhCL2, and FhCL5, from adult flukes in an ELISA, test of sera from sheep and cattle naturally infected with Fasciola hepatica, assessment of cross-reactive antibodies, overview. For sheep sera, the sensitivity is 100% for the three rFhpCLs, while for cattle sera, the highest sensitivity is obtained using rFhpCL2 (97%), being equal for both rFhpCL1 and rFhpCL5 (87.9%), after adjusting cut-offs for maximum specificity |
| 3.4.22.B61 | cathepsin L5 |
diagnostics |
analysis of the diagnostic values of the three different clades of cathepsin Ls, FhCL1, FhCL2, and FhCL5, from adult flukes in an ELISA, test of sera from sheep and cattle naturally infected with Fasciola hepatica, of cross-reactive antibodies, overview. For sheep sera, the sensitivity is 100% for the three rFhpCLs, while for cattle sera, the highest sensitivity is obtained using rFhpCL2 (97%), being equal for both rFhpCL1 and rFhpCL5 (87.9%), after adjusting cut-offs for maximum specificity |
| 3.4.22.27 | cathepsin S |
diagnostics |
an increased serum level of cathepsin S may serve as a biomarker for atherosclerosis and diabetes |
| 3.4.22.27 | cathepsin S |
diagnostics |
cathepsin S is a biomarker for adiposity and has relevance to atherogenesis |
| 3.4.22.43 | cathepsin V |
diagnostics |
the enzyme is a potential marker for certain colon tumors and breast cancer |
| 3.4.18.1 | cathepsin X |
diagnostics |
development of a highly sensitive and specific sandwich-type immunoassay for cathepsin X permitting both intra- and extracellular detection and quantification. Plasma and/or serum levels of (pro)cathepsin X may be a valuable diagnostic measure of certain disease states such as acute inflammation |
| 3.4.18.1 | cathepsin X |
diagnostics |
the enzyme is a molecular marker in bovine cumulus cells predictive of oocyte competence, functional and diagnostic relationship, overview |
| 3.4.18.1 | cathepsin X |
diagnostics |
Cathepsin X is an inflammatory marker |
| 1.1.99.18 | cellobiose dehydrogenase (acceptor) |
diagnostics |
key enzyme in biosensors |
| 1.1.99.18 | cellobiose dehydrogenase (acceptor) |
diagnostics |
the enzyme can be used for constructing biosensors |
| 1.1.99.18 | cellobiose dehydrogenase (acceptor) |
diagnostics |
the enzyme is used in amperometric biosensor |
| 3.2.1.4 | cellulase |
diagnostics |
labeled Trichoderma reesei cellulase is useful as a marker for Acanthamoeba cyst wall cellulose in infected tissues |
| 2.7.1.138 | ceramide kinase |
diagnostics |
putative prognostic marker in breast cancer, estrogen receptor negative patients with high ceramide kinase expression had a worse prognosis then those with low expression |
| 3.5.1.105 | chitin disaccharide deacetylase |
diagnostics |
the overall survival is high in lung cancer patients having low expression level of YDJC, while progression free survival is decreased in patients having high expression level of YDJC |
| 1.11.1.B2 | chloride peroxidase (vanadium-containing) |
diagnostics |
the observed bactericidal and virucidal activity of the alkalophilic P395D/L241V/T343A mutant of vanadium chloroperoxidase is an important step forward in the application of this robust enzyme as a component in disinfection formulations |
| 1.1.3.6 | cholesterol oxidase |
diagnostics |
the enzyme is used for a kinetic cholesterol assay for determination of cholesterol content in human serum, overview, the enzyme from Streptomyces is more effective than the enzyme from Brevibacterium |
| 1.1.3.6 | cholesterol oxidase |
diagnostics |
analytic tool for determining cholesterol in various samples |
| 1.1.3.6 | cholesterol oxidase |
diagnostics |
the enzyme is used to determine cholesterol in food and blood serum by coupling of the enzyme with peroxidase |
| 1.1.3.6 | cholesterol oxidase |
diagnostics |
determination of cholesterol, by rapid, cheap and reliable methods, is very important in clinical diagnosis because its level in blood is closely related to human health. A reproducible cholesterol biosensors is prepared based on the direct adsorption of ChOx onto gold substrates (ChOx-Au) |
| 1.1.3.6 | cholesterol oxidase |
diagnostics |
the enzyme is an important biotechnological tool for clinical diagnostics. It is also used for tracking intracellular cholesterol. Its utility is limited by the lack of an efficient temporal control of its activity. A rapamycin-inducible fluorescent cholesterol oxidase from Chromobacterium sp. DS-1 (split GFP-COase) is engineered. Induction by rapamycin allows temporal control over enzyme activity and rapidly leads to an efficient reduction of intracellular cholesterol. It is proposed that this drug-inducible split GFP-COase is a new tool to manipulate the cellular cholesterol content and gain insights into cholesterol-dependent proteins and cholesterol-related cell pathologies |
| 1.1.99.1 | choline dehydrogenase |
diagnostics |
study of prognostic biomarkers for breast cancer identifies the expression of CHD among three human genes controlled by estrogens, and shows that this is a strong predictor of the outcome of treatment with tamoxifen in early-stage (ER)-positive breast cancer patients |
| 2.7.1.32 | choline kinase |
diagnostics |
choline kinase alpha expression is a new prognostic factor that could be used to help identify patients with earlystage non-small-cell lung cancer who might be at high risk of recurrence, and to identify patients with favourable prognosis who could receive less aggressive treatment options or avoid adjuvant systemic treatment. |
| 2.7.1.32 | choline kinase |
diagnostics |
prognostic factor in human cancer |
| 2.3.1.6 | choline O-acetyltransferase |
diagnostics |
ChAT is selected as a marker of cholinergicneurons. In the CA1 region of hippocampus of mice, several of the insulin signaling-related proteins are co-located with ChAT, and most double immunoreactive positive cells are pyramidal cells |
| 2.7.7.15 | choline-phosphate cytidylyltransferase |
diagnostics |
CCT-alpha status is not predictive of outcome of neoadjuvant cisplatin-based chemotherapy response in patients with T2-T4 bladder cancer. In the control group with cystectomy only it has prognostic value |
| 3.1.1.8 | cholinesterase |
diagnostics |
BuChE is a possible marker for Alzheimer's disease |
| 3.1.1.8 | cholinesterase |
diagnostics |
butyrylcholinesterase activity is a sensitive and specific biomarker of Alzheimers disease (AD), BChE-associated amyloid-beta plaques has the potential as an improved AD biomarker. The predictive value of BChE as a biomarker for AD facilitates timely disease diagnosis and management |
| 3.1.1.8 | cholinesterase |
diagnostics |
O-ethyl S-2-diisopropylaminoethyl methyl phosphonothiolate (VX) forms phosphorylated adducts with enzyme BChE, inhibiting the enzyme. This adduct in human plasma can serve as a biomarker of exposure to nerve agents. Purification efficiency between the procainamide affinity gel method and immunomagnetic separation (IMS) for the nerve agent adduct of BChE in plasma is evaluated, the sample preparation is optimized by purifying BChE to measure biomarkers of human exposure to organophosphorus nerve agents. The purification efficiency of IMS is 5fold greater than that of the procainamide affinity gel method because the antibody conjugate with protein G magnetic beads ensures highly selective capture and high recovery of VX-inhibited BChE from plasma |
| 3.5.3.3 | creatinase |
diagnostics |
creatininase is used as clinical enzyme to measure creatinine. Spores co-expressing creatininase and creatinase mediate a two-step reaction from creatinine to urea (and sarcosine). An advantage of spore-encapsulated enzymes is that immobilized and stress-tolerant enzymes can be produced without purification |
| 3.5.3.3 | creatinase |
diagnostics |
important medical enzyme, used for clinical diagnosis of renal function because of its high substrate specificity |
